U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H19BrF2N2O3
Molecular Weight 477.299
Optical Activity NONE
Additional Stereochemistry Yes
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0
Stereo Comments AXIAL, RACEMIC

SHOW SMILES / InChI
Structure of PHA-797804

SMILES

CNC(=O)C1=CC(N2C(C)=CC(OCC3=CC=C(F)C=C3F)=C(Br)C2=O)=C(C)C=C1

InChI

InChIKey=KCAJXIDMCNPGHZ-UHFFFAOYSA-N
InChI=1S/C22H19BrF2N2O3/c1-12-4-5-14(21(28)26-3)9-18(12)27-13(2)8-19(20(23)22(27)29)30-11-15-6-7-16(24)10-17(15)25/h4-10H,11H2,1-3H3,(H,26,28)

HIDE SMILES / InChI

Molecular Formula C22H19BrF2N2O3
Molecular Weight 477.299
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein. The drug was developed by Pfizer for the treatment of inflammatory diseases. PH-797804 is being tested in phase II of clinical trials in patients with COPD, osteoarthritis, rheumatoid arthritis and post-herpetic neuralgia.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.
2011 Jul 1
Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.
2011 Jul 1
Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.
2011 Nov 24
Patents

Sample Use Guides

Chronic Obstructive Pulmonary Disease: PH-797804 should be orally administered at maximum dose of 10 mg. Neuralgia: 6 mg dose in oral capsule form, once daily for 28 days. Osteoarthritis: 6 mg once daily for 2 weeks. Rheumatoid Arthritis: the maximum dose is 10 mg taken once daily for 12 weeks.
Route of Administration: Oral
Rheumatoid arthritis synovial fibroblasts were treated with serial concentrations (10000–0.01 nM) of PH-797804 for 1 h, stimulated with 1 ng/ml IL-1 for 18 to 20 h at 37C to measure IL-1-beta induced PGE2 production. IC50 was 1.5 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:50:33 UTC 2023
Edited
by admin
on Fri Dec 15 15:50:33 UTC 2023
Record UNII
SI09I1V827
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHA-797804
Code English
BENZAMIDE, 3-(3-BROMO-4-((2,4-DIFLUOROPHENYL)METHOXY)-6-METHYL-2-OXO-1(2H)-PYRIDINYL)-N,4-DIMETHYL-
Systematic Name English
PH 797804
Code English
PH797804
Code English
Code System Code Type Description
EPA CompTox
DTXSID70207342
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
CHEBI
82715
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
FDA UNII
SI09I1V827
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
CAS
586379-66-0
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
PUBCHEM
22049997
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
SMS_ID
100000175093
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
ChEMBL
CHEMBL1088751
Created by admin on Fri Dec 15 15:50:33 UTC 2023 , Edited by admin on Fri Dec 15 15:50:33 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Ki
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY